IP Library Granted Patent US 10,196,615
Granted Patent B2
US 10,196,615 · App. 15/163,288 · Granted Feb 5, 2019

Virus purification and formulation process

Inventors: John J. Vicalvi, Jr. (Marlborough, MA); Edward G. Hayman (Hanover, NH); Joseph Makowiecki (Oxford, MA)
Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
C12N7/00C12N2770/24151C12N2770/24163
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,615
App. No.
15/163,288
Granted
Feb 5, 2019
Kind
B2
Abstract

Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.

Claims (10)

1. A process for making an essentially pure inactivated flavivirus preparation comprising:

a. obtaining a composition suitable for purification from a virus-infected Vero cell culture;

b. clarifying the composition obtained in step “a” by removing cells and cell debris from said composition by depth filtration;

c. subjecting the filtrate in step “b” to endo-nuclease digestion and 0.2 Micron Filtration sufficient to fragment Vero cell DNA followed by filtration;

d. purifying the filtrate obtained in step “c” via a cross-linked agarose matrix with a dextran sulfate functional group chromatography resin and a cross-linked agarose matrix with an octylamine ligand chromatography resin having a shell that excludes molecules with a molecular mass greater than approximately 700 kDa from passing through pores of the shell to achieve depyrogenation of said virus in said filtrate;

e. stabilizing and inactivating the viral product obtained in step “d” with an inactivating amount of β-PL;

f. after inactivating the viral product in step “e”, adjusting the temperature of the viral product to about 25° C. to about 30° C.;

g. filtering the product obtained in step “f”; and

h. formulating the product obtained in step “g” bound to alum.

2. The process of claim 1 wherein the flavivirus is Yellow Fever virus.

Assignments (3)
CHANGE OF NAME Recorded Aug 27, 2020
From: GE HEALTHCARE BIO-SCIENCES CORP.
To: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
Reel/Frame 053615/0305 →
MERGER Recorded May 26, 2016
From: XCELLEREX, INC.
To: GE HEALTHCARE BIO-SCIENCES CORP.
Reel/Frame 038731/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2016
From: VICALVI, JOHN; HAYMAN, EDWARD; MAKOWIECKI, JOSEPH
To: XCELLEREX INC.
Reel/Frame 038706/0325 →
Continuity (3)
Continuation 14423394
Provisional Application 61692956 · Aug 24, 2012
Related Publication 20160264943A1 · Sep 15, 2016
Cited By (1)
US 12,305,198